Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

BACKGROUND: Understanding the value of new anticoagulation therapies compared with existing therapies is of paramount importance in today’s cost-conscious and efficiency-driven health care environment. Edoxaban and rivaroxaban for stroke prevention in nonvalvular atrial fibrillation (NVAF) patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clinicoecon Outcomes Res
Main Authors: Miller, Jeffrey D, Ye, Xin, Lenhart, Gregory M, Farr, Amanda M, Tran, Oth V, Kwong, W Jackie, Magnuson, Elizabeth A, Weintraub, William S
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881922/
https://ncbi.nlm.nih.gov/pubmed/27284259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S98888
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados